Immutep Limited Share Price
NASDAQ: IMMPImmutep Limited Stock Performance
Immutep Limited Share Price Chart
About Immutep Limited
Immutep Ltd is a clinical-stage biotechnology company developing novel Lymphocyte Activation Gene-3 (LAG-3) related immunotherapies for cancer and autoimmune disease. It has a diversified product portfolio that harnesses LAG-3's ability to stimulate the body's immune response to fight cancer or suppress the immune system to treat autoimmune disease. The company is focused on advancing its product candidate, eftilagimod alfa (efti), through its registrational Phase three clinical trial towards marketing approval in first-line non-small cell lung cancer (1L NSCLC). The other product candidates in its portfolio include TACTI-003, AIPAC-003, TACTI-002, INSIGHT-005, and others, being developed as potential therapies for various cancers and autoimmune diseases.
Immutep Limited Historical Returns
| Month | Open | Close | Change % |
|---|---|---|---|
Oct 2026 | $4.52 | $3.85 | -18.19% |
Sep 2026 | $0.37 | $4.70 | +1,123.96% |
Aug 2026 | $0.36 | $0.38 | -0.78% |
Jul 2026 | $0.44 | $0.39 | -7.19% |
Jun 2026 | $0.43 | $0.42 | -3.92% |
May 2026 | $0.45 | $0.43 | -5.86% |
Apr 2026 | $0.36 | $0.46 | +30.59% |
Mar 2026 | $2.67 | $0.35 | -87.35% |
Feb 2026 | $2.82 | $2.79 | +2.01% |
Jan 2026 | $2.89 | $2.73 | -3.87% |
Dec 2025 | $1.99 | $2.85 | +38.44% |
Nov 2025 | $1.83 | $2.06 | +9.02% |